Kewaunee Scientific Reports Significant Q3 EPS Decline and Reduced Backlog
summarizeSummary
Kewaunee Scientific Corporation reported mixed third-quarter fiscal year 2026 results, with sales and pre-tax earnings increasing, but net earnings and diluted EPS falling significantly, alongside a notable decrease in its order backlog.
check_boxKey Events
-
Q3 Net Earnings and EPS Decline
Net earnings decreased by nearly 50% to $0.692 million, and diluted EPS fell to $0.23 from $0.45 in the prior year quarter.
-
Order Backlog Reduction
The order backlog decreased to $183.2 million as of January 31, 2026, down from $221.6 million in the prior year, signaling potential headwinds for future revenue.
-
Sales Growth and Pre-tax Earnings Improvement
The company reported a 3.3% increase in sales to $69.4 million and a 25.8% rise in pre-tax earnings to $1.6 million.
-
Improved Debt Profile
Long-term debt decreased, and the debt-to-equity ratio improved to 0.68-to-1 from 0.99-to-1, indicating stronger financial health.
auto_awesomeAnalysis
Kewaunee Scientific's third-quarter fiscal year 2026 results present a mixed picture for investors. While the company achieved modest sales growth and an increase in pre-tax earnings, the substantial decline in net earnings and diluted EPS, coupled with a significant year-over-year reduction in the order backlog, are key concerns. The CEO attributed the softness to seasonal factors, geopolitical uncertainty, and project delivery volatility, noting that the Nu Aire acquisition helped offset some of these challenges. Despite these headwinds, the company demonstrated an improved debt-to-equity ratio and reduced long-term debt, indicating balance sheet strengthening. Investors will likely focus on the declining profitability and backlog as indicators of future performance, while also considering the strategic benefits of the Nu Aire integration and debt management.
At the time of this filing, KEQU was trading at $35.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $117.5M. The 52-week trading range was $30.33 to $60.89. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.